Jade Biosciences Inc. (AVTE)
Delisted
28 Apr 2025
NASDAQ (NMS) NASDAQ (NMS) Primary $
2. 68
0
0%
$
77.68M Market Cap
- P/E Ratio
- Div Yield
981,795 Volume
- Eps
$ 2.68
Previous Close Day Range
2.63 2.77
Year Range
2.63 884.98
Want to track AVTE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Zacks | 2 years ago
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension.
Seekingalpha | 2 years ago
